DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 214 filers reported holding DENALI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $72,000 | +71.4% | 832 | -41.0% | 0.00% | – |
| Q2 2022 | $42,000 | -6.7% | 1,411 | 0.0% | 0.00% | – |
| Q1 2022 | $45,000 | -97.6% | 1,411 | -96.7% | 0.00% | -100.0% |
| Q4 2021 | $1,880,000 | -11.1% | 42,161 | +0.6% | 0.00% | 0.0% |
| Q3 2021 | $2,114,000 | -35.7% | 41,910 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $3,288,000 | +34.1% | 41,910 | -2.4% | 0.00% | 0.0% |
| Q1 2021 | $2,451,000 | -16.0% | 42,932 | +23.2% | 0.00% | -25.0% |
| Q4 2020 | $2,918,000 | +2029.9% | 34,841 | +814.2% | 0.00% | – |
| Q3 2020 | $137,000 | +48.9% | 3,811 | 0.0% | 0.00% | – |
| Q2 2020 | $92,000 | – | 3,811 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |